Equillium (EQ) Receives a Buy from H.C. Wainwright


H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Equillium (EQ) today and set a price target of $22.00. The company’s shares closed last Friday at $6.41.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 25.0% and a 51.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Biospecifics Technologies.

Currently, the analyst consensus on Equillium is a Strong Buy with an average price target of $19.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $27.05 and a one-year low of $2.20. Currently, Equillium has an average volume of 2.77M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline include EQ001, is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts